Please provide your email address to receive an email when new articles are posted on . The addition of blinatumomab to chemotherapy improved DFS for children with B-cell ALL. Researchers stopped ...

In the phase III ECOG-ACRIN E1910 study presented at the American Society of Hematology (ASH) annual meeting, consolidation chemotherapy with blinatumomab (Blincyto) improved overall survival in ...

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy ...

Please provide your email address to receive an email when new articles are posted on . “We can hopefully use these new agents in frontline therapy to increase the cure rate in adult ALL, and reduce ...

The lead investigator of the study from the Children's Oncology Group said the findings represent a new standard of care. Children with a first relapse of B-cell acute lymphoblastic leukemia (B-ALL) ...

Consolidation therapy with blinatumomab significantly improves overall survival (OS) in adult patients newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) who had no measurable residual ...

Recently published in haematology journal, HemaSphere, the ALLG ALL09 ‘SUBLIME’ study, was led by Associate Professor Matthew Greenwood of the Royal North Shore Hospital in Sydney and co-ordinated ...

KCCI EIGHT NEWS AT TEN. DES MOINES SECOND GRADER JUST CELEBRATED A MAJOR MILESTONE. KCCI LAURA TERRELL HAS THE STORY THAT WILL NO DOUBT BRING YOU JOY. GABE FULLER IS USED TO THIS ROUTINE. BY NOW.

Picture of acute lymphocytic leukemia or ALL cells in blood smear, analyze by microscope, 400x Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is ...

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in ...

COPENHAGEN, Denmark ― Monotherapy with the novel antibody blinatumomab (Blincyto, Amgen Inc) beat standard chemotherapy, significantly improving overall survival in adult patients with ...